Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 676

1.

Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.

Ferguson JJ, Antman EM, Bates ER, Cohen M, Every NR, Harrington RA, Pepine CJ, Theroux P; NICE-3 Investigators.

Am Heart J. 2003 Oct;146(4):628-34.

PMID:
14564315
3.

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.

Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators.

JAMA. 2003 Feb 19;289(7):853-63. Erratum in: JAMA. 2003 Apr 2;289(13):1638.

PMID:
12588269
4.

Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.

Dyke CM.

Am Heart J. 1999 Oct;138(4 Pt 2):307-16. Review.

PMID:
10502236
5.

Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes.

Vernon SM.

Cardiol Clin. 2001 May;19(2):235-52, vi. Review.

PMID:
11407108
6.

Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.

Bhatt DL, Topol EJ.

JAMA. 2000 Sep 27;284(12):1549-58. Review.

PMID:
11000650
7.

The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.

Lee DS, Bhatt DL, Moliterno DJ, Peacock WF, Ellis SG, Topol EJ.

J Invasive Cardiol. 2004 Feb;16(2):46-51.

PMID:
14760188
8.

An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.

Adgey AA.

Eur Heart J. 1998 Apr;19 Suppl D:D10-21. Review.

PMID:
9597518
9.

Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.

White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin BT, Cox DA, Pocock SJ, Ware JA, Manoukian SV, Lansky AJ, Mehran R, Moses JW, Stone GW.

J Am Coll Cardiol. 2008 Sep 2;52(10):807-14. doi: 10.1016/j.jacc.2008.05.036.

10.

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.

Blazing MA, de Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, DiBattiste PM, Palmisano J, Bilheimer DW, Snapinn SM, Ramsey KE, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM; 'A to Z' Investigators.

JAMA. 2004 Jul 7;292(1):55-64. Erratum in: JAMA. 2004 Sep 8;292(10):1178. Dosage error in article text.

PMID:
15238591
11.

Emergency coronary artery bypass surgery in the era of glycoprotein IIb/IIIa receptor antagonist use.

Pang JT, Fort S, Della Siega A, Cohen EA.

J Card Surg. 2002 Sep-Oct;17(5):425-31.

PMID:
12630543
12.

Real-world safety and efficacy of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.

Casterella PJ, Revenaugh JR, Burke JL, Pearson RR, Bair TL, May HT, Horne B, Anderson JL, Muhlestein JB.

J Invasive Cardiol. 2008 Mar;20(3):94-8.

13.
14.

A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.

Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER.

Circ Cardiovasc Interv. 2009 Jun;2(3):230-6. doi: 10.1161/CIRCINTERVENTIONS.108.847996. Epub 2009 Apr 21.

15.

Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).

Mukherjee D, Mahaffey KW, Moliterno DJ, Harrington RA, Yadav JS, Pieper KS, Gallup D, Dyke C, Roe MT, Berdan L, Lauer MS, Mänttäri M, White HD, Califf RM, Topol EJ.

Am Heart J. 2002 Dec;144(6):995-1002.

PMID:
12486423
18.

[Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].

Auer J, Berent R, Lassnig E, Weber T, Maurer E, Eber B.

Herz. 2003 Aug;28(5):393-403. Review. German.

PMID:
12928738
19.

Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.

Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators.

JAMA. 2004 Aug 11;292(6):696-703. Erratum in: JAMA. 2006 Jul 5;296(1):46.

PMID:
15304466
20.

Supplemental Content

Support Center